SpringWorks Therapeutics brings to Merck KGaA two FDA-approved drugs, both currently under regulatory review in Europe. Beyond their initial applications in rare tumors, these small molecules are also being studied as monotherapies and as part of combination treatments for certain cancers.
SpringWorks Therapeutics’ Gomekli is now FDA approved for treating tumors caused by the rare genetic disorder neurofibromatosis type 1. The approval comes as SpringWorks has emerged as a potential acquisition target.
The layout of your phlebotomy station can significantly impact efficiency. A well-thought-out setup ensures that every tool is within reach, minimizing unnecessary movement and reducing patient wait times.
SpringWorks Therapeutics drug Ogsiveo is now FDA-approved for treating desmoid tumors, a type of tumor affecting connective tissue. The regulatory decision makes the pill the first therapy approved specifically for treating this rare disorder.
“In a lot of ways, it starts with patient groups, who help us look at the landscape and understand where the science is that may not be organically happening in the industry right now,” said Lara Sullivan, founder and president of Pfizer spin-off SpringWorks.